KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Non-Current Deferred Tax Liability (2016 - 2019)

Arbutus Biopharma's Non-Current Deferred Tax Liability history spans 5 years, with the latest figure at $12.7 million for Q2 2019.

  • For Q2 2019, Non-Current Deferred Tax Liability fell 25.27% year-over-year to $12.7 million; the TTM value through Jun 2019 reached $12.7 million, down 25.27%, while the annual FY2017 figure was $16.9 million, 58.94% down from the prior year.
  • Non-Current Deferred Tax Liability for Q2 2019 was $12.7 million at Arbutus Biopharma, roughly flat from $12.7 million in the prior quarter.
  • Across five years, Non-Current Deferred Tax Liability topped out at $156.0 million in Q2 2015 and bottomed at $12.7 million in Q3 2018.
  • The 5-year median for Non-Current Deferred Tax Liability is $41.3 million (2016), against an average of $62.9 million.
  • The largest annual shift saw Non-Current Deferred Tax Liability crashed 71.8% in 2016 before it decreased 25.27% in 2019.
  • A 5-year view of Non-Current Deferred Tax Liability shows it stood at $146.3 million in 2015, then plummeted by 71.8% to $41.3 million in 2016, then crashed by 58.94% to $16.9 million in 2017, then fell by 25.27% to $12.7 million in 2018, then changed by 0.0% to $12.7 million in 2019.
  • Per Business Quant, the three most recent readings for ABUS's Non-Current Deferred Tax Liability are $12.7 million (Q2 2019), $12.7 million (Q1 2019), and $12.7 million (Q3 2018).